Clik here to view.
Bristol-Myers shares are sliding after some bad news on its lung cancer drug...
The competition over a new class of cancer drugs is heating up.On Thursday, drugmaker Bristol-Myers Squibb said that it wouldn't go for an accelerated US approval for a combination of its two...
View ArticleClik here to view.
The world's richest doctor's cancer moonshot plan is falling short
The world's richest doctor had a very bold plan.He'd assemble an unprecedented collaboration of companies, researchers, and doctors. Their mission: to vanquish cancer. By the year 2020, they'd build a...
View ArticleClik here to view.
There could be a surprising link between how people respond to a new cancer...
Cancer immunotherapy — treatments that harness the body's immune system to fight cancer — has been gaining traction in recent years as a new approach to treating the disease. But one of its major...
View ArticleClik here to view.
Carl Icahn just jumped into a $90 billion drug maker, and people are betting...
Activist investors are going after Bristol-Myers Squibb, a drugmaker with a $93 billion market cap.First, Jana Partners pressured the drugmaker into adding three new board members and announcing a...
View ArticleClik here to view.
A patch could fix your peanut-allergy problem
A treatment for one of the most common food allergies out there just got even more data that it's working.Roughly 1.5 million children in the US are allergic to peanuts, an allergy that can often be so...
View ArticleClik here to view.
Scientists are adopting a new battle plan in the war against cancer
In 2017, cancer might finally become number one. It would be an upset victory, given that heart disease has killed more people in the US every year for nearly a century. But it wouldn't exactly be a...
View ArticleClik here to view.
A small drug company that's trying to make cancer treatments safer just...
CytomX, a biotech that's developing safer ways to administer cancer immunotherapies, just got another $200 million from drug giant Bristol-Myers Squibb.Bristol-Myers has two drugs, Opdivo and Yervoy,...
View ArticleClik here to view.
A combination of cancer drugs work better together than on their own — but...
April 3 (Reuters) - Patients with advanced melanoma who received Bristol-Myers Squibb's immunotherapies Opdivo and Yervoy had improved overall survival compared with those on Yervoy alone, with 64...
View ArticleClik here to view.
A new kind of cancer treatment could be backfiring in some people
For doctors at the University of California, San Diego, it was seemingly a no-lose proposition: A 73-year-old patient’s bladder cancer was slowly progressing but he was generally stable and strong.He...
View ArticleClik here to view.
The FDA just approved a new drug that uses the body's immune system to treat...
May 1 (Reuters) - The U.S. Food and Drug Administration on Monday granted accelerated approval to AstraZeneca Plc's immuno-oncology drug to treat a type of bladder cancer in patients whose disease...
View ArticleClik here to view.
A key AstraZeneca drug reduced the risk of death in people with lung cancer...
LONDON (Reuters) - AstraZeneca's key immunotherapy drug durvalumab was shown to reduce the risk of stage III lung cancer worsening or causing death in a trial, the pharmaceutical company said on...
View ArticleClik here to view.
A promising new cancer treatment is facing a deadly setback
Cancer immunotherapy, or treatments that use the body's immune system, have been gaining traction in the past few years. That's especially true with a group of therapies called "checkpoint...
View ArticleClik here to view.
The FDA just took an entirely new approach to approving a cancer drug (LOXO,...
The FDA just approved a cancer drug that targets tumors based on genetic makeup as opposed to tissue type.On Tuesday, the agency approved pembrolizumab (also known as Keytruda) to treat "unresectable...
View ArticleClik here to view.
There's a race to get 2 revolutionary new cancer treatments on the market —...
Two cutting-edge treatments for blood cancers are poised to get approved by the end of the year. The highly personalized treatment is called CAR T-cell therapy. It's a type of cancer immunotherapy, or...
View ArticleClik here to view.
A cancer treatment that one expert called the 'most exciting thing I’ve seen...
A US Food and Drug Administration (FDA) advisory committee just gave a critical recommendation for a cutting-edge cancer therapy. Novartis went before the FDA on Wednesday for an advisory committee...
View ArticleClik here to view.
A former biotech executive who's living with terminal cancer wants to reset...
Michael D. Becker, a former biotech executive, knows a lot about cancer drug development. In 2015, he was diagnosed with head and neck cancer, which was caused by human papillomavirus (or HPV), a...
View ArticleClik here to view.
AstraZeneca plunges 16% after its lung cancer drug failed a key trial (AZN)
LONDON, July 27 (Reuters) - AstraZeneca's combination of two immunotherapy drugs, durvalumab and tremelimumab, failed to help patients as hoped in a closely watched advanced lung cancer trial, the...
View ArticleClik here to view.
Pharma giant Bristol-Myers Squibb just made another big bet on cancer...
Bristol-Myers Squibb, a company known for its cancer immunotherapy drugs, just acquired immunotherapy startup IFM Therapeutics. The deal is worth $300 million upfront, and if IFM's two drug programs...
View ArticleClik here to view.
Gilead just handed a revolutionary kind of cancer treatment a $12 billion...
Gilead is spending $12 billion to buy Kite Pharma, a biotech that has no approved therapies yet. The drugmaker's therapy that's a few months away from a possible approval is a highly personalized...
View ArticleClik here to view.
A cancer treatment that one expert called the 'most exciting thing I've seen...
The US Food and Drug Administration just approved a cutting-edge cancer therapy.On Wednesday, the FDA approved Novartis' Kymriah, also known as tisagenlecleucel, a treatment for pediatric acute...
View Article
